Medical (incl. medical device & pharma), US Foreign Corrupt Practices Act & Dodd Frank - Written by on Tuesday, November 23, 2010 3:23 - 0 Comments

Pharmaceutical businesses and the stark warning from the SFO

Print Friendly

Barry and Richard write on FCPA Compliance and Ethics Blog about the thinly veiled warning recently issued by the Director of the Serious Fraud Office, Richard Alderman to the pharmaceutical sector.

It has been well publicised that the pharmaceutical sector has been under increasing scrutiny from US regulators. Mr. Alderman spoke at a UK pharmaceutical conference about the industry, the Bribery Act and the SFO’s close co-operation with the US Department of Justice which is involved in a Foreign Corrupt Practices Act investigation into the pharmaceutical sector in the US.

Share Button

Comments are closed.

Brought to you by...

Barry Vitou &
Richard Kovalevsky Q.C.

The views expressed on this website are those of Barry Vitou & Richard Kovalevsky QC and/or our guest authors from time to time. Please see our terms of use

Our Tweets

Wednesday, June 6, 2018 9:13

Opinion: New Serious Fraud Office Director Appointment reflects Americanisation of UK Corporate Crime Enforcement a…

Monday, May 21, 2018 7:21

Lords to review Bribery Act over its burden on SMEs via @FT

Monday, May 21, 2018 7:21

UK anti-fraud agency struggles to find a new head via @FT

Monday, May 21, 2018 7:20

Lords to review Bribery Act over its burden on SMEs via @FT

Friday, May 18, 2018 13:59

City lawyer faces charges on money laundering rules